Analyzing Aptevo Therapeutics (APVO) and Spero Therapeutics (SPRO)

Aptevo Therapeutics (NASDAQ: APVO) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Profitability

This table compares Aptevo Therapeutics and Spero Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Aptevo Therapeutics 5.40% -28.03% -17.46%
Spero Therapeutics N/A N/A N/A

Valuation & Earnings

This table compares Aptevo Therapeutics and Spero Therapeutics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aptevo Therapeutics $36.43 million 1.93 -$112.41 million N/A N/A
Spero Therapeutics N/A N/A N/A N/A N/A

Spero Therapeutics has lower revenue, but higher earnings than Aptevo Therapeutics.

Insider & Institutional Ownership

34.1% of Aptevo Therapeutics shares are held by institutional investors. Comparatively, 25.5% of Spero Therapeutics shares are held by institutional investors. 15.6% of Aptevo Therapeutics shares are held by insiders. Comparatively, 13.9% of Spero Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings for Aptevo Therapeutics and Spero Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aptevo Therapeutics 0 0 1 0 3.00
Spero Therapeutics 0 1 4 0 2.80

Aptevo Therapeutics presently has a consensus price target of $6.00, indicating a potential upside of 82.93%. Spero Therapeutics has a consensus price target of $27.67, indicating a potential upside of 163.24%. Given Spero Therapeutics’ higher probable upside, analysts plainly believe Spero Therapeutics is more favorable than Aptevo Therapeutics.

Summary

Aptevo Therapeutics beats Spero Therapeutics on 5 of the 9 factors compared between the two stocks.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc. is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company’s technology is the ADAPTIR (modular protein technology) platform. The Company has approximately four products in the areas of hematology and infectious diseases, as well as various investigational-stage product candidates in immuno-oncology. The Company’s investigational-stage product candidates include MOR209/ES414, ES210, ES425, Otlertuzumab and 5E3. Its technology can produce monospecific and multispecific immunotherapeutic proteins that bind to various targets. The Company’s marketed products are WinRho SDF (Rho(D) Immune Globulin Intravenous (Human)), HepaGam B (Hepatitis B Immune Globulin Intravenous (Human)), VARIZIG (Varicella Zoster Immune Globulin (Human)), and IXINITY (coagulation factor IX (recombinant)).

Spero Therapeutics Company Profile

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing novel treatments for MDR bacterial infections. The Company is developing a portfolio of novel product candidates, including SPR994, Potentiator Platform (SPR741 and SPR206), and SPR720. SPR994 is novel oral formulation of tebipenem, a carbapenem-class antibiotic. SPR994 is effective against a broad spectrum of MDR bacterial infections, its initial focus is on the treatment of cUTIs. Potentiator platform that enables to develop drugs that expand the spectrum and potency of existing antibiotics, including inactive antibiotics, against Gram-negative bacteria. SPR720 is novel oral therapy product candidate designed for the treatment of NTM, a rare lung infection often occurring in patients with compromised immune systems, including HIV, or respiratory conditions, such as cystic fibrosis, asthma and bronchiectasis.

Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply